Description of the medicine: Leuprorelin (Leuprorelin)
Synonyms: Lucrin depot, Prostap, Lucrin depot, Prostap.
6-D-Leucine-9- (N-ethyl-L-prolinamide) -10-deglycinamide-luteinizing hormone releasing factor (porcine).
An analogue of gonadotropin releasing factor.
Available in the form of acetate (C 59 H 84 N 16 O 12 · C 2 H 4 O 2 ).
By action, it is close to buserelin (see).
After intramuscular administration, leuprorelin is released from the copolymer within 1 month, while during the first 7 days the content of sex hormones rises, and by the 21-28th day it decreases and remains at this level with subsequent administration of the drug.
Bioavailability is 75-98%, T Ѕ - 3 hours
It is used for hormone-dependent prostate cancer, as well as for uterine fibroids and endometriosis.
Available in the form of lyophilized microspheres in 3.75 and 7.5 mg vials complete with a solvent. The drug is administered intramuscularly or subcutaneously 1 time per month: for prostate cancer - 3.75 or 7.5 mg; with uterine fibroids and endometriosis - 3.75 mg. The course of treatment is not more than 6 months.
Possible side effects: headache, dizziness, sleep disturbance, dyspepsia, swelling of the face and legs, impaired vision and hearing, depression, decreased libido; in men - impotence, gynecomastia, testicular reduction; in women - vaginitis, acne, hirsutism, decreased bone density.
The drug is contraindicated in hormone-independent prostate cancer.